Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 23 2020 - 7:20AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of
Foreign Private Issuer
Pursuant to Rule 13a-16 or
15d-16
of the Securities Exchange Act of 1934
Date of Report: November 23, 2020
Commission File Number: 001-39307
Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)
2101
Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Legend Biotech Announces New Appointment to the Board of Directors and Resignation of Dr. Fangliang
Zhang
On November 23, 2020, Legend Biotech Corporation (the Company) issued a press release announcing a new appointment to the
Companys Board of Directors and the resignation of Dr. Fangliang Zhang. The press release is attached to this Form 6-K as Exhibit 99.1.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
LEGEND BIOTECH CORPORATION
(Registrant)
|
|
|
|
|
November 23, 2020
|
|
|
|
By:
|
|
/s/ Ying Huang
|
|
|
|
|
|
|
Ying Huang, Ph.D.
|
|
|
|
|
|
|
Chief Executive Officer and Chief Financial Officer
|
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Jul 2023 to Jul 2024